阿美替尼联合贝伐珠单抗对非小细胞肺癌细胞的作用研究  

Effect of Almonertinib Combined with Bevacizumab on Non-Small Cell Lung Cancer Cells

作　　者：朱怡璇 汪洋 屠文莲[2] 曹玮[2] Zhu Yixuan;Wang Yang;Tu Wenlian;Cao Wei(College of Pharmacy,Dali University,Dali 671000,China;Department of Pharmacy,The First People's Hospital of Yunnan Province,Kunming 650000,China;Department of General Surgery,Dazhou Central Hospital,Dazhou 635000,China)

机构地区：[1]大理大学药学院,云南671000 [2]云南省第一人民医院药学部,云南650000 [3]达州市中心医院普外科,达州635000

出　　处：《成都医学院学报》2025年第2期186-191,共6页Journal of Chengdu Medical College

基　　金：云南省科学技术厅科技计划项目-基础研究计划项目(No:2022201AY070001-238);云南省第一人民医院临床药学中心开放课题(No:2023YJZX-YX18)。

摘　　要：目的探究阿美替尼联合贝伐珠单抗对非小细胞肺癌(NSCLC)细胞的作用。方法体外培养NSCLC细胞株A549、H1975,分别加入不同浓度阿美替尼(0、1、5、15、50、150、500 mg/L)和贝伐珠单抗(0、1、10、30、100、300、1000 mg/L);采用CCK8法、流式细胞术、划痕实验、Transwell实验测定A549、H1975细胞在阿美替尼、贝伐珠单抗及二者联合用药作用下细胞的增殖率、凋亡率、迁移能力和侵袭能力。结果CCK-8实验结果显示,阿美替尼组、贝伐珠单抗组A549、H1975细胞增殖率低于对照组,且联合用药组A549细胞增殖率低于单药组(P<0.05);人工划痕实验结果显示,阿美替尼组、贝伐珠单抗组及二者联合用药组A549、H1975细胞的迁移率低于对照组(P<0.05),且联合用药组A549、H1975细胞的迁移率低于单药组(P<0.05);Transwell实验表明,阿美替尼组、贝伐珠单抗组及二者联合用药组A549、H1975细胞的侵袭率均低于对照组,仅在A549细胞侵袭实验中,联合用药组细胞的侵袭率低于单药组(P<0.05);流式细胞术实验结果显示,阿美替尼、贝伐珠单抗及二者联合组A549、H1975细胞凋亡率高于对照组(P<0.05)。结论与单一用药相比,阿美替尼联合贝伐珠单抗在抑制肿瘤细胞迁移、侵袭方面更具优势。Objective This study investigates the effect of almonertinib combined with bevacizumab on non-small cell lung cancer(NSCLC)cells.Methods NSCLC cell lines A549 and H1975 were cultured in vitro,and different concentrations of almonertinib(0,1,5,15,50,150,500 mg/L)and bevacizumab(0,1,10,30,100,300,1000 mg/L)were added,respectively.Cell counting kit(CCK)-8,flow cytometry,scratch assay,and Transwell assay were utilized to determine the proliferation rate,apoptosis rate,migration ability,and invasion ability of A549 and H1975 cells under the treatment of almonertinib or bevacizumab alone or in combination,respectively.Results CCK-8 experiment results showed that almonertinib and bevacizumab inhibited the proliferation of A549 and H1975 cells,and the combination group exhibited greater inhibition effect on the proliferation of A549 cells compared to the monotherapy groups(P<0.05).The results of artificial scratch test showed that almonertinib,bevacizumab,and their combination therapy inhibited the migration of A549 and H1975 cells,and the combination therapy showed statistical significance in inhibiting migration compared to monotherapy(P<0.05).Transwell assay revealed that almonertinib,bevacizumab,and their combination therapy inhibited the invasion of A549 and H1975 cells,and the combination therapy demonstrated greater inhibition effect on the invasion of A549 cells compared to monotherapy(P<0.05).The results of flow cytometry experiments showed that almonertinib,bevacizumab,and their combination therapy induced apoptosis in A549 and H1975 cells(P<0.05).Conclusion Compared with monotherapy,the combination of almonertinib and bevacizumab is more effective in inhibiting the migration and invasion of tumor cells.

关 键 词：非小细胞肺癌细胞 血管内皮生长因子 增殖 迁移 侵袭 凋亡 

分 类 号：R734.2[医药卫生—肿瘤]